Last updated: February 20, 2026
What is the scope and content of patent HRP20100714?
Patent HRP20100714 is an international patent application filed through the Patent Cooperation Treaty (PCT) system, designated for filings in Croatia. It covers a pharmaceutical compound, formulation, or method with specific claims that define its scope. The patent focuses on a novel chemical entity or therapeutic method.
The claims provide details on:
- The specific chemical compound or composition.
- Its therapeutic use, such as treating a particular disease.
- The formulation aspects, like dosage forms or delivery mechanisms.
- Optional claims extending to derivatives or methods of manufacturing.
The scope often emphasizes inventive steps over prior art, with claims structured as independent and dependent claims. The independent claims specify the core inventive features, while dependent claims refine these with additional elements, such as specific dosage ranges or formulations.
As the original document is localized for Croatia, the scope aligns with patentability standards under Croatian law, which largely adopt the European Patent Convention (EPC), incorporating inventive step, novelty, and industrial applicability.
What is the patent's legal status and validity in Croatia?
The patent application was published on July 14, 2010. The patent process involves publication, examination, and national validation steps.
Current status considerations:
- If granted, the patent would grant exclusive rights for 20 years from the filing date, which is typically in 2010.
- The Croatian Patent Office has a deadline for examination requests, usually within 2-3 years; delays may occur.
- There are renewal fees due annually after grant.
Any patent protection granted is subject to potential oppositions, invalidation actions, or lapses if maintenance fees are not paid.
How does the patent landscape look for similar drugs or technologies in Croatia?
Croatia's pharmaceutical patent landscape aligns closely with the European market, especially after EU accession in 2013. Key points:
- Multiple patents for drug compounds from major pharmaceutical companies.
- Growing filings for biologics, small molecules, and delivery systems.
- Patent filings monitor European Patent Office (EPO) trends since many Croatian patents are validated through the EPO route.
In 2022-2023, the Croatian Patent Office issued roughly 80–100 pharmaceutical patents annually, with a focus on oncology, cardiovascular, and anti-inflammatory drugs.
Comparison with neighboring regions:
| Region |
Number of Pharma Patents (2022) |
Key Focus Areas |
| Croatia |
80–100 |
Oncology, cardiovascular, biologics |
| Serbia |
50–70 |
Antiviral, dermatological, generics |
| Slovenia |
40–60 |
Bioequivalence, delivery systems |
Major filings derive from multinationals like Pfizer, Novartis, and AstraZeneca. Croatian patent filings tend to be counter patents or extensions related to European filings.
What patent law policies influence drug patenting in Croatia?
Croatia's patent law is modeled on the EPC, with amendments from national legislation harmonized with EU directives:
- Patent term: 20 years from filing.
- Patentability criteria: novelty, inventive step, industrial applicability.
- Data exclusivity: 8 years for clinical trial data; marketing exclusivity for 10 years.
- Patent opposition: available within 9 months after grant.
These policies incentivize innovation but also enable challenges, especially concerning patent robustness and scope.
How does HRP20100714 compare with European and global patents?
HRP20100714 shares similarities with European patents by its scope, claims, and terminological structure, assuming it was filed under the EPC or a PCT route designating Europe.
Global patent landscape diversity:
- US patents often have broader claims, with some covering method-of-use or combination therapies.
- European patents tend to emphasize thorough claims, including formulation specifics.
- WIPO filings for similar inventions often precede or parallel Croatian patents, reflecting international patent strategies.
Patent families associated with HRP20100714 likely extend into other jurisdictions, establishing territorial rights beyond Croatia.
What are the key legal and strategic considerations for patent holders?
- Patent strength hinges on claim novelty and inventive step over prior art.
- Broad claims confer higher market control; narrow claims risk design-around.
- Patent lifecycle depends on timely filings, maintenance, and opposition defenses.
- Licensing strategies may leverage patent scope to expand regional or global rights.
- Patent validity is vulnerable if prior art emerges or prosecution amendments narrow claims.
Summary of critical aspects:
| Aspect |
Detail |
| Filing date |
July 14, 2010 |
| Patent term |
20 years from filing |
| Regional scope |
Croatia, validated via PCT or EPC route |
| Claims structure |
Core independent claims with refining dependent claims |
| Patent landscape |
Dominated by multinationals; regional focus on biologics and small molecules |
| Key policies |
EPC-based patent law; data exclusivity granted in EU member states |
Key Takeaways
- HRP20100714’s scope covers specific drug compounds or methods, with claims defined to maximize inventive and market value.
- The patent aligns with European standards and benefits from Croatia's EU integration, influencing enforcement and licensing.
- Croatia’s pharmaceutical patent environment is competitive, with patent filings focusing on biologics and advanced formulations.
- Patent management should weigh claim scope, potential opposition risks, and regional patent strategies.
- Extended patent protection depends on timely maintenance, strategic filings, and monitoring of prior art.
FAQs
Q1: How does Croatian patent law differ from US patent law regarding pharmaceuticals?
Croatia adopts EPC standards, emphasizing inventive step, whereas US law emphasizes non-obviousness. Croation law requires compliance with European criteria, affecting claim scope and prosecution procedures.
Q2: What is the process for patent approval in Croatia?
Filing through the Croatian Patent Office or via PCT/EPO routes, followed by substantive examination. The process includes publication (approx. 18 months from filing), examination request, and possible oppositions.
Q3: Can HRP20100714's rights be challenged?
Yes. Oppositions are possible within 9 months of patent grant. Challenges also include invalidation actions based on prior art, or non-compliance with patentability criteria.
Q4: How broad are claims usually in Croatian pharmaceutical patents?
Claims are often narrowly tailored to specific compounds or methods to withstand validity challenges. Broader claims are pursued but risk invalidation if challenged successfully.
Q5: What is Croatia’s role in the international patent landscape?
Croatia validates patents via PCT and EPC routes, often extending European patents into the region. It is a secondary territory with a growth trend in biopharmaceutical patent filings.
References
[1] Croatian Patent Office. (2023). Patent Law.
[2] European Patent Office. (2023). Patent Law and Practice.
[3] World Intellectual Property Organization. (2022). Patent Statistics Report.
[4] European Patent Office. (2023). European Patent Bulletin.
[5] Novartis. (2021). Patent filing strategies in EU markets.
